Jump to any asset
850 assets, updated daily
As of September 12, 2026, Forte Biosciences, Inc. (FBRX) trades at $76.99. CleaRank Financial AI rates it Hold with a fair value of $76.99, in line with the current price. Wall Street's consensus target is $77.00 across 4 analysts. RSI at 69 is in neutral territory, and the price is above its 50-day average of $55.12.
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. NASDAQ
$76.99
0.00 (0.00%)
At close: Aug 28, 4:00 PM EDT
AI Analyst Consensus
56 / 100
Forte Biosciences (FBRX) is currently trading at $76.99, precisely at its median analyst target price of $77.00, indicating a lack of immediate upside according to Wall Street. The company's stock has shown positive momentum, trading above its 50-day and 200-day moving averages ($55.12 and $32.86), supported by a bullish RSI of 68.89. Despite this technical strength, fundamental analysis reveals a challenging picture, with negative EPS of -4.57 and zero reported revenue growth, contrasting sharply with sector averages for P/E and revenue growth. Insiders have demonstrated a moderate buying signal, with $254.8K in total purchases versus no reported sales in recent filings, suggesting some level of confidence from management. However, the company's forward-looking growth estimates are also negative, with a projected -11.6% compound annual growth rate over the next five years. This combination of technical strength and fundamental concerns positions FBRX in a 'Hold' territory, awaiting clearer signs of a sustainable growth trajectory or a significant catalyst.
FBRX Price Analysis
Market Metrics
Open
$76.99
Day Range
$76.99 to $76.99
Prev Close
$76.99
52-Week Range
$10.11 to $77.20
Market Cap
$1.63B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
FBRX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, FBRX beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
FBRX Analysis
Company's Health
3/5
12-Month Analyst Target
+2.50% Upside
Median of 4 analysts (12-month)
$78.91
AI Technical Analysis
Forte Biosciences (FBRX) is exhibiting bullish momentum, trading above its 50-day and 200-day moving averages ($55.12 and $32.86), and its 20-day EMA ($73.94). The Relative Strength Index (RSI) stands at a bullish 68.89, indicating strong upward price action without yet reaching overbought territory. The MACD is also positive at 5.295, further supporting the current uptrend. Key support levels are established by the 50-day and 200-day SMAs, while the current price hovers near the 20-day EMA, suggesting immediate resistance might be found around the $74 to $77 range.
ProTips
- Insiders have been net buyers of Forte Biosciences (FBRX) stock, investing $254.8K in recent transactions, which may signal underlying confidence in the company's future prospects.
- The stock is trading above its 50-day and 200-day moving averages ($55.12 and $32.86), indicating positive short-term and medium-term technical trends, but investors should monitor for any potential pullbacks towards these support levels.
- Given the company's negative EPS and zero revenue growth, investors should closely watch for any news regarding pipeline advancements or strategic shifts that could fundamentally alter its growth trajectory.
Key Catalysts
Bullish
Insider Buying Activity
Insiders have made net purchases totaling $254.8K, indicating a moderate level of confidence in the company's prospects.
Source: Insider TransactionsBullish
Positive Technical Momentum
The stock is trading above its 50-day and 200-day moving averages ($55.12 and $32.86), supported by a bullish RSI of 68.89, suggesting continued upward price pressure.
Source: Technical AnalysisBearish
Persistent Negative EPS
Forte Biosciences has consistently reported negative EPS, with the latest quarter showing -0.97 against an estimate of -0.88, highlighting ongoing profitability challenges.
Source: Earnings ReportsBearish
Zero Revenue Growth
The company is reporting no revenue growth, significantly lagging behind the sector average and raising concerns about its business model's viability.
Source: Financial DataMarket Outlook
The base case scenario for Forte Biosciences (FBRX) over the next 6-12 months suggests continued trading around its current levels, given its median analyst target price of $77.00 aligns with the current stock price. The bullish technical momentum, with the stock trading above key moving averages and a strong RSI, may provide some support for near-term price stability. However, the fundamental challenges of negative EPS and zero revenue growth present a significant overhang, limiting the potential for substantial upside without a clear catalyst for growth or profitability. The thesis could be altered by a breakthrough in the company's drug development pipeline, leading to positive clinical trial results and future revenue streams, which would likely trigger a re-rating by analysts and investors. Conversely, continued operational losses without a clear path to revenue generation could lead to a downward revision of price targets and increased selling pressure, especially if the company requires further capital raises. The negative forward-looking growth estimates also pose a substantial risk to any bullish outlook.
Key Statistics
| Market Cap | 1.63B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -4.57 |
| Dividend Yield | 0.00% |
| 52 Week High | 77.20 |
| 52 Week Low | 10.11 |
Forte Biosciences (FBRX) presents a valuation paradox, with a negative EPS of -4.57 rendering its P/E ratio of -16.35 (negative due to EPS of $-4.57). The company reports zero revenue growth, a stark contrast to the Healthcare sector's median revenue growth of 8.1%, raising concerns about its ability to generate sales. While the stock is trading at its median analyst target price of $77.00, offering no immediate upside, the lack of revenue and persistent losses suggest a premium valuation based on future potential rather than current performance. The company's balance sheet strength is not detailed, but the negative EPS and zero revenue growth indicate significant operational challenges. The forward-looking growth estimates are also concerning, with a projected -11.6% CAGR over the next five years, suggesting a potential contraction in business scale. This fundamental picture, characterized by losses and stagnant revenue, warrants caution despite the positive technical indicators.
Earnings & Growth Analysis
Forte Biosciences (FBRX) most recently reported an EPS of -0.97 for the quarter ending August 12, 2026, missing the analyst estimate of -0.88 by 10.23%. This follows a pattern of consistent EPS misses, including -1.24 against -1.16 in May 2026 and -1.45 against -1.15 in March 2026. While the company did show a positive surprise of 7.48% in November 2025, the overall trend indicates a struggle to meet earnings expectations.
Key Risks
Forte Biosciences (FBRX) faces significant risks stemming from its persistent negative EPS and complete lack of revenue growth, which are not aligned with the broader Healthcare sector's performance. The company's forward-looking growth estimates are also negative, suggesting a potential long-term contraction. Also, the stock is trading precisely at its median analyst target price, offering no immediate upside and highlighting the market's current equilibrium between technical strength and fundamental weakness.
Technical Indicators
| RSI (14) | 68.89 |
|---|---|
| MACD | 5.30 |
| SMA 50 | 55.12 |
| SMA 200 | 32.86 |
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($55.12) above the 200-day SMA ($32.86), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.10
Weak correlation
Nasdaq 100 (QQQ)
+0.08
Weak correlation
Bitcoin (BTC)
+0.14
Weak correlation
Gold (XAU)
+0.01
Weak correlation
Check Custom Correlation
Calculating correlation...
FBRX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$76.22
Slight discount to current
Wait for small dip
AGGRESSIVE
$76.99
At current price
Enter now if confident
Risk Management
STOP LOSS
$67.36
MAX LOSS
-11.6%
Volatility-Adjusted Stop Loss
Calculated based on RSI (68.9) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$78.51
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$80.03
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$82.32
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
FBRX is classified as a high-volatility asset (Daily Vol: 7.76%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 12, 2026.Growth of $10,000
A $10,000 investment in FBRX in April 2017 would be worth about $165 today, compared with about $33,089 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in FBRX today could grow to about $2,117 by 2036 in the base case, with a bull case near $16,059 and a bear case around $279. Projections are statistical simulations, not guarantees.
FBRX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $41.37 for FBRX by 2030 in the base case, from $76.99 today (0.5x over 4 years). The downside path ends near $11.48. These are outcomes of a Monte Carlo simulation run on FBRX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $34.73 | $65.92 | $125 |
| 2028 | $22.80 | $56.44 | $140 |
| 2029 | $15.93 | $48.32 | $147 |
| 2030 | $11.48 | $41.37 | $149 |
| 2031 | $8.45 | $35.42 | $148 |
| 2032 | $6.31 | $30.33 | $146 |
| 2033 | $4.77 | $25.97 | $141 |
| 2034 | $3.63 | $22.23 | $136 |
| 2035 | $2.78 | $19.03 | $130 |
| 2036 | $2.15 | $16.30 | $124 |
Method: 10,000 simulated price paths using FBRX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
FBRX Insider Trading Analysis
Bought
$254.8K
1 Transactions
Sold
None
No open-market sells
Insiders
2
Active Traders
Avg Transaction
$254.8K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2026 | RILEY ANTONY A
Chief Financial Officer
|
Grant | 375 | - |
| Jul 1, 2026 | WAGNER PAUL A
Chief Executive Officer
|
Grant | 1.3K | - |
| Apr 1, 2026 | RILEY ANTONY A
Chief Financial Officer
|
Grant | 375 | - |
| Apr 1, 2026 | WAGNER PAUL A
Chief Executive Officer
|
Grant | 1.3K | - |
| Dec 31, 2025 | RILEY ANTONY A
Chief Financial Officer
|
Grant | 375 | - |
| Dec 31, 2025 | WAGNER PAUL A
Chief Executive Officer
|
Grant | 1.3K | - |
| Dec 30, 2025 | RILEY ANTONY A
Chief Financial Officer
|
Buy | 9.7K | $254.8K |
| Oct 1, 2025 | RILEY ANTONY A
Chief Financial Officer
|
Grant | 375 | - |
| Oct 1, 2025 | WAGNER PAUL A
Chief Executive Officer
|
Grant | 1.3K | - |
| Jul 1, 2025 | RILEY ANTONY A
Chief Financial Officer
|
Grant | 375 | - |
Page 1 of 1
Frequently Asked Questions
Is Forte Biosciences (FBRX) stock a buy right now?
Forte Biosciences (FBRX) is currently rated a 'Hold' with a consensus score of 56. The stock is trading at $76.99, which is exactly at its median analyst target price of $77.00, offering no immediate upside. While insiders have been net buyers, the company faces significant fundamental challenges including negative EPS and zero revenue growth.
What is Forte Biosciences' (FBRX) price forecast for 2030?
Based on Monte Carlo simulations, Forte Biosciences' (FBRX) stock price is projected to be $41.37 in 2030 under a base case scenario, with a downside projection of $11.48 and an upside projection of $149.04. These are statistical outcomes and not guaranteed price targets.
What are the biggest risks facing Forte Biosciences (FBRX)?
The primary risks for Forte Biosciences (FBRX) include its persistent negative earnings per share, a complete absence of revenue growth, and negative forward-looking growth estimates. The stock is also trading at its median analyst target price, limiting immediate upside potential.
How is Forte Biosciences (FBRX) performing technically?
Technically, Forte Biosciences (FBRX) shows bullish momentum, trading above its 50-day and 200-day moving averages ($55.12 and $32.86) with a bullish RSI at 68.9. The stock is currently trading near its 20-day EMA, indicating positive short-term price action.
What is Forte Biosciences' (FBRX) consensus rating?
The consensus rating for Forte Biosciences (FBRX) is 'Hold', supported by a consensus score of 56 out of 100. This reflects a mixed view among the four Wall Street analysts covering the stock.
Are there any recent earnings surprises for Forte Biosciences (FBRX)?
Forte Biosciences (FBRX) has recently missed earnings expectations, reporting an EPS of -0.97 against an estimate of -0.88 for the quarter ending August 12, 2026. This follows a pattern of earnings misses in previous quarters.
What is the revenue growth outlook for Forte Biosciences (FBRX)?
Forte Biosciences (FBRX) currently reports zero revenue growth, which is significantly below the Healthcare sector median of 8.1%. Forward-looking revenue estimates also show no growth for the current and next quarters, and a negative compound annual growth rate of -11.6% is projected over the next five years.